Breast cancer
Conditions
Interventions
Gold Standard:Past clinical treatment records. Pathology report records.
Index test:Preoperative Bilirubin and Enzymatic Indices
Sponsors
The First Hospital Of Jiaxing
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Female; 2.Age >= 18 years; 3.Pathologically confirmed at our institution as primary invasive breast cancer between January 2019 and May 2026. 4.Patients who underwent breast cancer surgery and SLNB at this institution, in whom the SLN demonstrated micrometastases or macrometastases, and who subsequently underwent ALND with definitive pathological results. 5.It enables the determination of whether additional positive non-sentinel lymph nodes are present in an ALND specimen. 6.Preoperatively, blood biochemical parameters available for calculating the BEI were present, including TBIL, ALT, AST, and LDH. 7.The clinical data satisfy the primary analytical requirements of this study.
Exclusion criteria
Exclusion criteria: 1.Patients undergoing surgery following neoadjuvant therapy; 2.Pure Ductal Carcinoma In Situ (DCIS) or DCIS with Microinvasion; 3.Cases with indeterminate outcome variables or in whom ALND was not performed, precluding determination of additional NSLNM status. 4.Patients lacking key preoperative blood parameters, rendering the calculation of primary study endpoints impossible. 5.Preoperative conditions that may significantly affect hematological, inflammatory, coagulation, or biochemical parameters—such as acute infection or fever, active autoimmune disease, hematological disorders, or recent major trauma, surgery, or thrombotic events—are present. 6.Severe hepatic and renal function abnormalities (ALT or AST exceeding the upper limit of normal by more than 2-fold; TBIL exceeding the upper limit of normal by more than 1.5-fold; or LDH significantly elevated above the upper limit of normal). 7.Individuals undergoing long-term use of systemic corticosteroids, immunosuppressants, or therapeutic-dose anticoagulants, where the investigator determines that such use is likely to significantly affect relevant parameters. 8.Other circumstances deemed unsuitable for inclusion in the analysis by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the receiver operating characteristic curve (AUC) for predicting additional NSLNM after ALND using BEI; | — |
Secondary
| Measure | Time frame |
|---|---|
| BEI Sensitivity;BEI Specificity; | — |
Countries
China
Contacts
Public ContactXiang Lu
The First Hospital Of Jiaxing
Outcome results
None listed